Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-κB ligand, osteoprotegerin, and cathepsin K

Journal of Rheumatology

Volumn 32, Issue 4, 2005, Pages 713-720

  Mandelin, Jami ^a   Li, Tian Fang ^a   Hukkanen, Mika ^a   Liljeström, Mikko ^a   Salo, Jari ^b   Santavirta, Seppo ^b   Konttinen, Yrjö T ^b,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^d COXA Hospital for Joint Replacement ^*  (Finland)

Author keywords

Cathepsin K; Fibroblast; Implants; Osteoprotegerin; Rankl; Vitamin D

Indexed keywords

CALCITRIOL; CATHEPSIN K; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONE DESTRUCTION; CELL LYSATE; CELL STIMULATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FIBROBLAST; FIBROBLAST CULTURE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; JOINT CAPSULE; MALE; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOTAL HIP PROSTHESIS; TRABECULAR BONE; UPREGULATION; WESTERN BLOTTING;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; CALCITRIOL; CARRIER PROTEINS; CATHEPSINS; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOKINES; FEMALE; FIBROBLASTS; GLYCOPROTEINS; HIP PROSTHESIS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; OSTEOLYSIS; OSTEOPROTEGERIN; PROSTHESIS FAILURE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 17144380821     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Murray DW, Rushton N. Macrophages stimulate bone resorption when they phagocytose particles. J Bone Joint Surg Br 1990;72:988-92.
2. Kadoya Y, Kobayashi A, Ohashi H. Wear and osteolysis in total joint replacements. Acta Orthop Scand 1998;278 Suppl:1-16.
3. Takagi M. Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Acta Orthop Scand 1996;271 Suppl:3-29.
4. Goldring SR, Schiller AL, Roelke M, Rourke CM, O'Neil DA, Harris WH. The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg Am 1983;65:575-84.
5. Goldring SR, Jasty M, Roelke MS, Rourke CM, Bringhurst FR, Harris WH. Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement. Arthritis Rheum 1986;29:836-42.
6. Konttinen YT, Takagi M, Mandelin J, et al. Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. J Bone Miner Res 2001; 16:1780-6.
7. Haynes DR, Crotti TN, Potter AE, et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br 2001;83:902-11.
8. Mandelin J, Li T-F, Liljestrom M, et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement implants. J Bone Joint Surg Br 2003;85:1196-201.
9. Itonaga I, Sabokbar A, Murray DW, Athanasou NA. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. Ann Rheum Dis 2000;59:26-31.
10. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
11. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998:95:3597-602.
12. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-7.
13. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
14. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
15. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-61.
16. Nagai M, Sato N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem Biophys Res Commun 1999;257:719-23.
17. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000:15:2-12.
18. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappa-B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
19. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
20. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
21. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002:347:175-84.
22. Cundy T, Hegde M, Naot D, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002;11:2119-27.
23. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-8.
24. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
25. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4.
26. Willard D, Chen WJ, Barrett G, et al. Expression, purification, and characterization of the human receptor activator of NF-kappa-B ligand (RANKL) extracellular domain. Protein Expr Purif 2000;20:48-57.
27. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000;141:4768-76.
28. Thomas GP, Baker SU, Eisman JA, Gardiner EM. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol 2001; 170:451-60.
29. Kitazawa S, Kitazawa R. Epigenetic control of mouse receptor activator of NF-kappa B ligand gene expression. Biochem Biophys Res Commun 2002;293:126-31.
30. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-9.
31. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53.
32. Takahashi N, Akatsu T, Udagawa N, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988;123:2600-2.
33. Mandelin J, Liljestrom M, Li T-F, et al. Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. J Biomed Mater Res 2005;73B: (in press).
34. Crotti TN, Smith MD, Findlay DM, et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NF kappa B, RANK ligand and osteoprotegerin. Biomaterials 2004;25:565-73.
35. Garnero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998;273:32347-52.
36. Hou WS, Li Z, Gordon RE, et al. Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol 2001;159:2167-77.
37. Hou WS, Li W, Keyszer G, et al. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum 2002;46:663-74.